Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma - Retrospective analysis and identification of prognostic factors in 488 patients
Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma - Retrospective analysis and identification of prognostic factors in 488 patients
复制标题
DOI：
10.1002/cncr.23332
复制
发表时间：
2008-04-01
期刊：
影响因子：
6.2
通讯作者：
Judson, Ian
中科院分区：
文献类型：
--
作者：
Karavasilis, Vasillos;Seddon, Beatrice M.;Judson, Ian
背景。在一大群接受常规姑息治疗的晚期软组织肉瘤 (STS) 患者中研究了姑息化疗的疗效。方法。从皇家马斯登医院的肉瘤数据库中识别出 1991 年至 2005 年间因晚期和/或转移性疾病接受过一线化疗的 STS 患者。患有尤文肉瘤、横纹肌肉瘤、促结缔组织增生性小圆细胞瘤和胃肠道间质瘤的患者被排除在研究之外。 结果。总共有 488 名患者（242 名男性，246 名女性）符合研究标准。中位年龄为 49 岁，大多数 (83%) 因转移性疾病接受化疗。最常见的组织学亚型是平滑肌肉瘤（35%）、滑膜肉瘤（13%）、脂肪肉瘤（10%）和恶性纤维组织细胞瘤（10%）。总共有 61% 的人接受了单药化疗，通常是阿霉素。据报告，33% 的患者出现客观缓解（滑膜肉瘤患者为 53%）； 22% 的患者疾病稳定，45% 的患者获得“临床获益”（客观反应 + 疾病稳定>= 6 个月）。中位缓解持续时间为 9 个月，中位治疗后总生存期 (OS) 为 12 个月。在多变量分析中，年龄
BACKGROUND. The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft-tissue sarcomas (STS) treated on routine palliative protocols.METHODS. Patients with STS who had first-line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database. Patients with Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, and gastrointestinal stromal tumors were excluded from the study.RESULTS. In all, 488 patients (242 male, 246 female) fulfilled the study criteria. The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease. The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%). In all, 61% received single-agent chemotherapy, usually doxorubicin. An objective response was reported in 33% of patients (53% in those with synovial sarcoma); 22% had stable disease and 45% derived 'clinical benefit' (objective responses + stable disease for >= 6 months). Median duration of response was 9 months and median posttreatment overall survival (OS) was 12 months. In multivariate analysis, age